Related Experiment Video
Updated: Sep 20, 2025
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
14.1K
Repetitive Transcranial Magnetic Stimulation targeted with MRI based neuro-navigation in major depressive episode: a
Bruno Millet1, Ghina Harika-Germaneau2, Redwan Maatoug3
1Institut du Cerveau et de la Moelle, UMR, CNRS, INSERM, Sorbonne Université et Département de Psychiatrie Adulte, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Plos One
|May 27, 2025
Summary
Neuro-navigation did not improve high-frequency transcranial magnetic stimulation (rTMS) efficacy for Major Depressive Episode. This study found no significant difference in treatment response rates compared to standard targeting methods.
Area of Science:
- Neuroscience
- Psychiatry
- Medical Technology
Background:
- High-frequency transcranial magnetic stimulation (rTMS) is a common treatment for Major Depressive Episode (MDE).
- Neuro-navigation systems, using MRI, have been proposed to optimize rTMS targeting and improve efficacy.
- Previous small studies suggested a significant benefit of neuro-navigation.
Purpose of the Study:
- To evaluate if MRI-based neuro-navigation enhances the efficacy of HF-rTMS for MDE compared to a standard targeting technique.
- To compare treatment response rates, remission rates, and depression symptom severity between the two targeting methods.
Main Methods:
- A multicenter, patient- and evaluator-blinded randomized controlled trial (RCT) involving 105 patients with MDE.
- Patients received 10 sessions of HF-rTMS targeting the left dorsolateral prefrontal cortex (DLPFC).
- Intervention group used MRI-based neuro-navigation; control group used the standard 5 cm technique. Primary outcome was response rate at 44 days post-treatment.
Main Results:
- No statistically significant difference in treatment response rates was observed between the neuro-navigation group (31.8%) and the standard group (35.6%).
- Secondary outcomes, including remission rates and depression scores (BDI, SRRS), also showed no significant differences at 14 and 44 days.
- Adverse event rates were similar between the two groups.
Conclusions:
- This RCT failed to demonstrate the superiority of MRI-based neuro-navigation for optimizing HF-rTMS efficacy in MDE.
- The findings contradict previous suggestions of improved outcomes with neuro-navigation.
- Limitations include a potentially small sample size and a possibly suboptimal number of rTMS sessions.
